Heart failure drug dapagliflozin under Real-World microscope in greece
NCT ID NCT05635331
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study in Greece observed 257 adults with heart failure who were prescribed dapagliflozin as part of their routine care. Researchers tracked how long patients stayed on the drug, any changes in their other heart medications, and how their quality of life changed over time. The goal was to understand how this approved medication works in everyday practice, outside of a controlled clinical trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dapagliflozin
What this could lead to
If successful, this study could provide real-world insights into how dapagliflozin is used and tolerated in everyday heart failure care, potentially improving treatment guidelines.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient selection and other factors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Alexandroupoli, 68100, Greece
-
Research Site
Athens, 11526, Greece
-
Research Site
Athens, 11527, Greece
-
Research Site
Athens, 11528, Greece
-
Research Site
Athens, 12462, Greece
-
Research Site
Athens, 14233, Greece
-
Research Site
Athens, 17674, Greece
-
Research Site
Chania, 73300, Greece
-
Research Site
Heraklion, 71409, Greece
-
Research Site
Ioannina, 45445, Greece
-
Research Site
Ioannina, 45500, Greece
-
Research Site
Pátrai, 26504, Greece
-
Research Site
Thessaloniki, 54636, Greece
-
Research Site
Thessaloniki, 54642, Greece
-
Research Site
Thessaloniki, 56429, Greece
-
Research Site
Thessaloniki, 57010, Greece